TRAIL has been considered a promising target for cancer therapy because it mediates activation of the extrinsic apoptosis pathway in a tumor-specific manner by binding to and trimerizing its functional receptors, DR4 or DR5. The gene discussed is TNFRSF10A; the disease is neoplasm.